@prostatecanceruk's early detection claims, fact-checked

What did @prostatecanceruk actually say?

The video makes three core claims: that "one in four black men will get prostate cancer," that this is "double the risk of other men," and that black men face a higher risk of late diagnosis. The creators also stated there is "no screening programme for prostate cancer" in the UK and urged men to check their risk online. These are public health claims with real consequences, so they deserve a close look rather than a celebrity pass.

The messenger here matters. Using MOBO Awards hosts to reach Black British audiences is a deliberate and reasonable strategy. Prostate cancer kills around 12,000 men in the UK annually, and awareness gaps in Black communities are well-documented. The intent is clearly sound. But good intentions do not automatically mean accurate statistics.

Does the science back this up?

Mostly, yes. The "one in four" figure is supported by current estimates. The claim holds up reasonably well against published data, though the precise figure varies depending on the source and methodology.

Prostate Cancer UK and Cancer Research UK both cite a lifetime risk of approximately 1 in 4 for Black men in the UK, compared to roughly 1 in 8 for white men. That is broadly consistent with the "double the risk" framing used in the video. The data comes partly from studies like the PROCESS cohort study (Chinegwundoh et al., 2006, BJU International) and has been reinforced by more recent NHS England data. The late diagnosis point also stands up. Research published by Ben-Shlomo et al. (2008, British Journal of Cancer) found Black men were more likely to present with advanced disease, partly due to later presentation and access barriers. The NHS has acknowledged this disparity formally.

What did they get wrong (or right)?

The "no screening programme" line is accurate but could use more context. They got the absence of a national programme right. They did not explain why, which matters.

The UK does not have a national prostate cancer screening programme, and this is not an oversight. The UK National Screening Committee has repeatedly reviewed the evidence and declined to recommend population-wide PSA testing because the PSA test has a high false-positive rate and can lead to overdiagnosis and overtreatment of cancers that would never have caused harm. This was reconfirmed in the 2021 UK NSC review. Saying there is no screening without that context could mislead viewers into thinking they are being failed by the system, rather than understanding it is a deliberate, evidence-based decision with its own trade-offs. The video's call to "check your risk" online using the Prostate Cancer UK risk checker is actually a more targeted and defensible approach than blanket PSA screening, which is worth saying plainly. That nuance got left on the floor.

What should you actually know?

The risk checker the video points to is a legitimate, evidence-based tool, but visiting your GP is still the necessary next step if your risk comes back elevated.

Prostate Cancer UK's online risk checker uses age, ethnicity and family history to stratify risk. It is not a diagnostic test. If you are a Black man over 45, or any man over 50 with a family history of prostate cancer, current guidance from NICE (NG131, updated 2023) supports having an informed conversation with your GP about PSA testing. Symptoms can include difficulty urinating, frequent urination at night and blood in urine or semen, but early prostate cancer often has no symptoms at all, which is precisely why the risk-check conversation matters. On the TRT connection: testosterone and prostate cancer have a complicated relationship. Historically, testosterone was considered contraindicated in men with prostate cancer. More recent evidence, including work by Morgentaler and Traish (2009, European Urology), has challenged the old "androgen hypothesis," but TRT in men with known or suspected prostate cancer still requires specialist oversight. If you are on or considering TRT, prostate health monitoring is part of responsible clinical management, not optional.

Bottom line verdict

This video is largely accurate and the public health intent is legitimate. The "one in four" and "double the risk" statistics are supported by current data. The late diagnosis point is real and documented. The absence of a national screening programme is correctly stated. The main gap is context around why there is no screening programme, which could have been explained in ten seconds and would have made the message stronger, not weaker. Credit where it is due: pointing people toward a risk checker rather than demanding a blanket blood test is actually the more defensible public health position, even if the video does not explain that. The creators got more right than wrong.